Accentia Secures Exclusive Global Rights to Revimmune II-71
Medarex and Compugen Ink Collaborative Agreement for
Therapeutic Antibody II-72
SRI and Telik Sign License Agreement for Drug Development II-73
China Biopharma Signs Agreement with Chinese Biopharmaceutical
Firm II-73
Kirin and Astellas Ink Licensing Agreement for Anti-CD40
Antagonistic mAb II-74
QSV and Artielle Sign Contract to Produce RTL-1000 II-74
JDRF and MacroGenics Form Partnership II-75
GSK and Genmad Sign Partnership Agreement for HuMaxCD20 II-75
Biocon Enters into Joint Venture Agreement with Neopharma II-76
Pipex Pharmaceuticals Acquires Remaining Stake in Effective
Pharmaceuticals II-76
Astellas Acquires Worldwide Rights for Amevive(R) II-77
Biogen Acquires Fumapharm II-77
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy II-77
7. FOCUS ON SELECT GLOBAL PLAYERS II-78
Abbott Laboratories (USA) II-78
Amgen Inc. (USA) II-78
Bayer Schering Pharma AG (Germany) II-79
Biogen Idec Inc. (USA) II-80
Bristol-Myers Squibb Company (USA) II-81
Elan Corporation, plc (Ireland) II-82
Eli Lilly And Company (USA) II-83
F. Hoffmann-La Roche AG (Switzerland) II-83
Chugai Pharmaceutical Co., Ltd. (Japan) II-84
Genentech, Inc. (USA) II-85
GlaxoSmithKline plc (UK) II-86
Johnson & Johnson, Inc. (USA) II-87
Merck Serono SA (Switzerland) II-88
Novartis AG (Switzerland) II-88
Sanofi-aventis SA (France) II-89
Schering-Plough Corporation (USA) II-90
Shire Pharmaceuticals Group plc (Ireland) II-90
Teva Pharmaceuticals Industries Limited (Israel) II-91
UCB Pharma (Belgium) II-92
8. GLOBAL MARKET PERSPECTIVE II-93
Table 8: World Recent
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |